EXOZYMES INC. Defined Contribution Plan, Cost
EXOZYMES INC. (EXOZ) reported Defined Contribution Plan, Cost of $72.13 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-08-13
- EXOZYMES INC. defined contribution plan, cost for the quarter ending 2026-06-30 was $35.81K, a 2.38% decline year-over-year.
- EXOZYMES INC. defined contribution plan, cost for the quarter ending 2026-03-31 was $36.32K, a 16.51% decline year-over-year.
- EXOZYMES INC. defined contribution plan, cost for the quarter ending 2025-12-31 was $33.32K, a 21.90% increase year-over-year.
- EXOZYMES INC. defined contribution plan, cost for the quarter ending 2025-09-30 was $37.59K, a 37.62% increase year-over-year.
- EXOZYMES INC. defined contribution plan, cost for fiscal 2025 was $151.09K, a 35.71% increase from fiscal 2024.
- EXOZYMES INC. defined contribution plan, cost for fiscal 2024 was $111.34K.
| Period end | Defined Contribution Plan, Cost 3 month | Defined Contribution Plan, Cost 6 month | Defined Contribution Plan, Cost 9 month | Defined Contribution Plan, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $35.81K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $72.13K 10-Q · filed 2026-08-13 | $105.45K derived: sum of 3 quarters · filed 2026-08-13 | $143.03K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $36.32K 10-Q · filed 2026-05-14 | $69.64K derived: sum of 2 quarters · filed 2026-05-14 | $107.23K derived: sum of 3 quarters · filed 2026-05-14 | $143.91K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $33.32K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $70.90K derived: sum of 2 quarters · filed 2026-03-30 | $107.58K derived: sum of 3 quarters · filed 2026-08-13 | $151.09K 10-K · filed 2026-03-30 |
| 2025-09-30 | $37.59K 10-Q · filed 2025-11-13 | $74.27K derived: sum of 2 quarters · filed 2026-08-13 | $117.77K 10-Q · filed 2025-11-13 | $145.11K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $36.68K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $80.19K 10-Q · filed 2026-08-13 | $107.52K derived: sum of 3 quarters · filed 2026-08-13 | $134.83K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $43.51K 10-Q · filed 2026-05-14 | $70.84K derived: sum of 2 quarters · filed 2026-05-14 | $98.15K derived: sum of 3 quarters · filed 2026-05-14 | |
| 2024-12-31 | $27.33K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $54.64K derived: sum of 2 quarters · filed 2026-03-30 | $111.34K 10-K · filed 2026-03-30 | |
| 2024-09-30 | $27.31K 10-Q · filed 2025-11-13 | $84.00K 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | $56.69K 10-Q · filed 2025-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |